The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." https://aronoyxe202888.ambien-blog.com/46985424/elite-investor-pharma-a-risky-investment